Genelux   Report issue

For profit Phase 3
Founded: San Diego CA United States (2001)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2008
NCT00794131
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Genelux Corporation | Genelux GmbH

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 1)

Fallopian Tube Neoplasms (Phase 1)

Head and Neck Neoplasms (Phase 1)

Mesothelioma (Phase 1)

Ovarian Neoplasms (Phase 1)

Peritoneal Neoplasms (Phase 2)

Pleural Effusion (Phase 1)

Pleural Effusion, Malignant (Phase 1)

Vaccinia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 8